香港股市 已收市

GOSS Jan 2026 1.500 put

OPR - OPR 延遲價格。貨幣為 USD。
加入追蹤清單
0.80000.0000 (0.00%)
收市:10:08AM EDT
全螢幕
正在載入互動式股價圖表...
  • InvestorPlace

    The Penny Stock Pundits: 3 Companies Poised to Become the Talk of Wall Street

    Do you have any penny stocks in your portfolio? If you don’t, you might want to consider it with any speculative money sitting on the sidelines. Penny stocks are usually those of small-cap, or even micro-cap companies with little revenue and are frequently not profitable. That’s enough to steer away many investors. But a little research can help you sort out the companies with little hope of growth versus those that may be a diamond in the rough. Remember, companies such as Amazon (NASDAQ:AMZN)

  • Benzinga

    Gossamer Bio Collaborates With Italian Drugmaker Chiesi To Advance Lung Health Solutions Worldwide

    Gossamer Bio Inc (NASDAQ:GOSS) and Italy-based Chiesi Farmaceutici S.p.A, have entered a global collaboration and license agreement to develop and commercialize seralutinib. This global collaboration combines the strengths of both Chiesi and Gossamer to support ongoing work in pulmonary arterial hypertension (PAH) and to accelerate the development of pulmonary hypertension associated with interstitial lung disease (PH-ILD). “Seralutinib is a potential paradigm-shifting therapy in PAH and PH-ILD,

  • Reuters

    UPDATE 1-Gossamer Bio and Chiesi Group to collaborate in therapy for lung condition

    Gossamer Bio said on Monday it will collaborate with Italian drugmaker Chiesi Group to develop and commercialize its therapy seralutinib in multiple indications related to high blood pressure due to constriction of lung arteries. The therapy is currently in late-stage development for the treatment of pulmonary arterial hypertension (PAH), which affects about 40,000 people in the United States. Gossamer is to receive $160 million in development reimbursement payment and is eligible to receive up to $146 million in regulatory and $180 million in sales milestones as part of the deal.